Brief: Xortx Announces Positive Topline Results From Part 2 Pharmacokinetics Bridging Study
22/08/2022 13:10
Aug 22 (Reuters) - XORTX Therapeutics Inc XRTX.V :
* XORTX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PART 2
PHARMACOKINETICS BRIDGING STUDY
* XORTX THERAPEUTICS INC - NO DRUG RELATED ADVERSE OR
SERIOUS
ADVERSE EVENTS RELATED TO ORAL ADMINISTRATION OF OXYPURINOL
* XORTX THERAPEUTICS INC - PHASE 3 REGISTRATION TRIAL, WITH
INITIATION OF PATIENT DOSING SCHEDULED FOR FIRST HALF 2023
Source text for Eikon: ID:nGNX3hzBhY
Further company coverage: XRTX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering